Pioneering the future of immunotherapy by reprogramming T cells in vivo
Our scalable therapeutic regimens are purpose-built to treat solid tumors and hematological cancers that respond poorly to existing immunotherapies.
Our in-house, off-the-shelf, CAR T-cell gene therapy platform works in vivo to treat solid tumors and hematologic malignancies at every stage.
News + Resources
We work at the leading edge of cancer immunotherapy. Visit our news and resources page to learn more about our scientific journey and the evolution of our company.
Together, we are advancing the future of immunotherapy to change the lives of every patient bearing the burden of cancer. Learn more about our team of experts.